» Articles » PMID: 36995478

Effect of Limosilactobacillus Reuteri ZJF036 on Growth Performance and Gut Microbiota in Juvenile Beagle Dogs

Overview
Journal Curr Microbiol
Specialty Microbiology
Date 2023 Mar 30
PMID 36995478
Authors
Affiliations
Soon will be listed here.
Abstract

This experiment investigated the effects of Limosilactobacillus reuteri ZJF036 on growth performance, serum biochemical parameters, and gut microbiota in beagle dogs. Sixteen 75 ± 5-day-old healthy male beagles (4.51 ± 1.37 kg) were randomly divided into two groups; the experimental group (L1) and the control group (L0), and then fed with or without a basal diet containing L. reuteri ZJF036 (10 CFU/g), respectively. The results showed that there was no significant difference in daily weight gain between the two groups (P > 0.05). However, we found that L. reuteri ZJF036 decreased Chao1 index and ACE index and increased the relative abundance of Firmicutes and Fusobacteria (P < 0.05) compared to the L0 group. In addition, we also found that the ratio of Firmicutes to Bacteroidetes was decreased in L1 group. Furthermore, the relative abundance of Lactobacillus increased, while that of Turicibacter and Blautia decreased in L1 group (P < 0.05). In conclusion, L. reuteri ZJF036 appeared to regulate the intestinal microbiota of beagle dogs. This study revealed the potential use of L. reuteri ZJBF036 as a probiotic supplement for beagle dogs.

Citing Articles

Gut Probiotics and Health of Dogs and Cats: Benefits, Applications, and Underlying Mechanisms.

Yang Q, Wu Z Microorganisms. 2023; 11(10).

PMID: 37894110 PMC: 10609632. DOI: 10.3390/microorganisms11102452.

References
1.
Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B . Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8):506-14. DOI: 10.1038/nrgastro.2014.66. View

2.
Shi S, Qi Z, Sheng T, Tu J, Shao Y, Qi K . Antagonistic trait of Lactobacillus reuteri S5 against Salmonella enteritidis and assessment of its potential probiotic characteristics. Microb Pathog. 2019; 137:103773. DOI: 10.1016/j.micpath.2019.103773. View

3.
Saulnier D, Santos F, Roos S, Mistretta T, Spinler J, Molenaar D . Exploring metabolic pathway reconstruction and genome-wide expression profiling in Lactobacillus reuteri to define functional probiotic features. PLoS One. 2011; 6(4):e18783. PMC: 3084715. DOI: 10.1371/journal.pone.0018783. View

4.
Francavilla R, Lionetti E, Castellaneta S, Ciruzzi F, Indrio F, Masciale A . Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study. Aliment Pharmacol Ther. 2012; 36(4):363-9. DOI: 10.1111/j.1365-2036.2012.05180.x. View

5.
Pernica J, Steenhoff A, Mokomane M, Moorad B, Lechiile K, Smieja M . Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial. PLoS One. 2017; 12(10):e0185177. PMC: 5633142. DOI: 10.1371/journal.pone.0185177. View